Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at email@example.com and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
Boehringer Ingelheim has completed a pilot project to assess whether it is best served by its current electronic laboratory notebook technology. The process led to Boehringer deciding to phase out use of multiple in-house systems and replace them with IDBS' E‑WorkBook Suite.
Dr. Patrick Soon-Shiong has teamed up with the University of Oxford and others to further the United Kingdom's plan to build the "NASA of biomedicine." Some of the £141 million ($227 million) investment is earmarked for establishing computing infrastructure to support the U.K.'s genomics project.
Geisinger Health System has added another component to the genomic variant database it is helping to create as part of a $25 million National Institutes of Health initiative. The new addition gives patients the option to submit their genetic test results and other health information to a registry.
The National Science Foundation has awarded Cornell University a grant to cut the time it takes to transfer data.
While there is a well-established path from seed funding to exit for web startups, genomics plays with big ambitions require investors with deep pockets and an appetite for risk. Bryan Johnson seemingly has both and has set up a $100 million fund with the objective of turning "crazy" ideas into "viable" businesses.
In a week during which 23andMe showed results from a clutch of its research programs at the American Society of Human Genetics annual meeting, it also tasked an industry veteran with winning new partnerships.
Microsoft has taken a lead from its co-founder Bill Gates' philanthropic efforts. The computing giant is making its Azure cloud platform available to Ebola researchers who need help with the storage and analysis of data.
Faced with the challenge of how to handle data from the 100,000 exomes it intends to sequence, Regeneron has struck a deal with DNAnexus to access cloud-based infrastructure.The biotech is working with DNAnexus through the Regeneron Genetics Center it established for the sequencing project.
The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.